Wiseheart Medval Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2021

Location

Beijing China

Primary Industry

Biotechnology

About

Based in Beijing, China and founded in 2021, Wiseheart Medval operates as an innovative biopharmaceutical company, focusing on cell therapy for neurological diseases. The company built a GMP-grade cell product manufacturing plant in Beijing's Zhongguancun Life Science Park. It has cooperated with Xuanwu Hospital. In June 2022, the company raised an undisclosed amount in angel funding from new investor Green Pine Capital Partners. In February 2024, Wiseheart Medval closed a pre-series A funding. The company uses reprogramming technology and non-integrating systems to obtain neural stem cells (iNSC) directly induced from human peripheral blood single nucleated cells or fibroblasts, and simultaneously and directionally differentiate them into dopaminergic neural precursor cells (iNSC-DAP). Its core products, Dopaminergic Neural Precursor Cells (iNSC-DAP) Injection, can treat Parkinson's disease with clinical intervention through stereotactic transplantation clinical technology. This technology allows for autologous or allogeneic cell therapy, avoiding the ethical issues involved in embryonic stem cell harvesting. The company will focus on the development of next-generation stem cell therapies for neurological disorders and validation of clinical efficacy.

Current Investors

Green Pine Capital Partners, Jiuzhi Capital, BCT Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Healthcare IT

Website

www.wiseheartmed.com

Verticals

HealthTech

Company Stage

Angel & Seed

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.